A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD)
Latest Information Update: 14 Jun 2023
At a glance
- Drugs Levodopa (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Acronyms SPAN-PD
- Sponsors Acorda Therapeutics
- 27 Apr 2023 Results of Subgroup Analyses of Effect of Treatment With Levodopa Inhalation Powder (CVT-301) 84mg by Severity of OFF Symptoms, presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 18 Sep 2022 Results of sub group analysis presented at the 26th International Congress of Parkinson's Disease and Movement Disorders.
- 26 Apr 2022 Results of sub group analysis presented at the 74th Annual Meeting of the American Academy of Neurology 2022